Cadient Group

Share this article:
Company Profile
Cadient Group is an interactive marketing network focused on the healthcare industry. Our companies align client needs with relevant innovation to deliver meaningful experiences and measurable results. Cadient Group business units include: Cadient Interactive—a digital marketing agency for healthcare companies seeking to harness the full potential of interactive marketing; and GEL Interactive Technologies—a technology provider offering proprietary software and services that align brand teams, activate advocates, and influence customers. Cadient Interactive specializes in custom-created interactive services to help clients reach higher performance at the brand, franchise, and corporate level. GEL Interactive Technologies promotes collaboration across various healthcare communities, utilizing robust portals and other event-focused technology tools to share information, shape opinions, and accelerate relationships. Our strategic consultancy and technology development offerings further differentiate Cadient Group. Our strategic insight helps clients better utilize multi-channel marketing to enhance connections with consumer and professional audiences. We help you integrate the latest interactive technologies—while realizing the full potential of your brand. With Cadient Group, you'll Experience Results.

Services and Offerings
Cadient Group offers an ever-broadening array of digital agency services, technology-driven solutions, and strategic consultancy to companies specializing in pharmaceutical and bioscience therapies, diagnostics and devices, consumer healthcare brands, and professional audiences. Cadient Group capitalizes on the innovative nature of digital media to enhance and integrate consumer and professional campaigns.
Our services include:
  • Consulting for eMarketing strategies
  • Website and application development
  • Key Opinion Leader services
  • Consumer relationship marketing
  • Professional relationship marketing
  • Collaborative portals for thought leader advocacy and speaker faculty management
  • Educational kiosks
  • Exhibit-based experiential marketing products
  • Media strategy, planning, and placement services
  • Marketing research and analytics
  • Usability testing
  • Site architecture redesign
  • Search engine marketing and optimization
  • E-mail marketing
  • Multi-media and video production/editing
Case Study
Novartis Vaccines, the makers of FLUVIRIN®, wanted an interactive add-on component to its FluSource.com educational site. Cadient Group's strategic recommendation included the concept of sponsoring a FluFlix Video Contest on YouTube.com to create a unique market voice for our client. This Web 2.0 tactic was leveraged to acquire user-generated content, and increase discussion around the need for vaccination. Contestants could submit original videos about their flu-related experience in different categories. Cadient Group produced two videos to promote the contest and serve as sample submissions; these videos received more than 750,000 views by interested contestants. The contest inspired dozens of entries, with more than 12,000 YouTube page views during the contest period. In partnership with Cadient Group, Novartis Vaccines surpassed its brand goals and experienced ground-breaking results in the consumer community.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...